P.11.19 Phase 2b, dose-ranging study of ataluren (PTC124®) innonsense mutation Duchenne muscular dystrophy – results of a post hoc analysis of change in %-predicted 6-min walk distance

✍ Scribed by McDonald, C.M.; Henricson, E.K.; Abresch, R.T.; Elfring, G.L.; Barth, J.; Peltz, S.W.; Reha, A.

• Book ID: 123509132
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 50 KB
• Volume: 23
• Category: Article
• ISSN: 0960-8966
• DOI: 10.1016/j.nmd.2013.06.580